Buscar
Mostrando ítems 1-3 de 3
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
(Taylor & Francis, 2014-07-07)
[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel.
METHODS: This multi-centre ...
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
(Elsevier, 2015-03)
[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ...
Role of taxanes in advanced prostate cancer
(Springer, 2016-02-08)
[Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence ...